Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Uterine Leiomyomata (Fibroids)

Interventions

DRUG

PRA-027

PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days

Trial Locations (2)

Pfizer Investigational Site, Miami

Pfizer Investigational Site, Beverly Hills

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00543790 - Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women | Biotech Hunter | Biotech Hunter